Scancell Holdings plc (AIM: SCLP), the late-stage clinical biotechnology company developing cancer immunotherapies, announced on 19 November 2026 that all resolutions proposed at its Annual General Meeting were duly passed. The AGM result confirms routine shareholder approval across all matters put to the vote, providing corporate continuity for the business as it advances its clinical pipeline. Investors in the AIM-listed oncology specialist will be watching progress across its ImmunoBody® and Moditope® platforms as the company moves through late-stage development.
Key Points
- Scancell Holdings plc (AIM: SCLP) — late-stage clinical biotechnology company listed on AIM
- All resolutions proposed at the Annual General Meeting held on 19 November 2026 were duly passed
- No financial figures or specific resolution details were disclosed in the announcement
- Investors may be watching continued clinical progress with inzitagene plasmivec and Modi-1 across active trials
All AGM Resolutions Passed at Scancell's 19 November 2026 Shareholder Meeting
Scancell Holdings plc confirmed that its Annual General Meeting, held on 19 November 2026, concluded with all proposed resolutions receiving the necessary shareholder approval. The company did not disclose the specific resolutions tabled, the voting breakdown, or the margins by which individual resolutions were passed. AGM outcomes of this nature are a standard element of corporate governance for AIM-listed companies and indicate that shareholders raised no material objections to the matters put before them. The result was communicated via a Regulatory News Service announcement, fulfilling the company's disclosure obligations under AIM rules.
Scancell's ImmunoBody® and Moditope® Platforms Underpin the Clinical Pipeline
Scancell develops targeted, off-the-shelf active immunotherapies through two proprietary platforms: ImmunoBody® and Moditope®. Its lead asset, inzitagene plasmivec, is a DNA ImmunoBody® that has demonstrated a favourable safety profile and clinically meaningful activity both as a monotherapy in a Phase 1 trial and in combination with checkpoint therapies in a Phase 2 trial in patients with melanoma. Modi-1, a Moditope peptide, is currently being evaluated in a Phase 2 study targeting head and neck as well as renal cancers, broadening the company's oncology reach beyond its initial melanoma focus.
Genmab Licensing Agreement Highlights Commercial Potential of GlyMab® Antibody Portfolio
Beyond its immunotherapy platforms, Scancell is advancing a pipeline of high-affinity GlyMab® antibodies that target tumour-specific glycans. Two of these antibodies have been licensed to Genmab A/S, described in the announcement as an international biotechnology company and global leader in the antibody therapeutics space, for further development. The licensing arrangement with Genmab represents a notable validation of Scancell's antibody technology and provides a potential non-dilutive revenue stream, though specific financial terms of the licence were not disclosed in this announcement. The company did not disclose this figure in the announcement.
CEO Phil L'Huillier Leads as Scancell Advances Towards Potential Late-Stage Data Readouts
Scancell is led by Chief Executive Officer Phil L'Huillier, with Panmure Liberum serving as the company's Nominated Adviser and Joint Broker alongside WG Partners LLP as Joint Broker. With Phase 2 trials active in melanoma, head and neck cancer, and renal cancer, the company's near-term investor interest will centre on clinical data updates rather than the AGM procedural outcome itself. As a late-stage clinical biotechnology company, Scancell carries the inherent risk that trial outcomes may not support progression to regulatory submission or commercialisation.




Please wait processing your request...